Which joints are commonly affected in individuals with ferritin levels greater than 1000 µg/L?

Common Joints Affected by High Ferritin (>1000 µg/L)

In patients with ferritin >1000 µg/L, the most commonly affected joints are the ankles (69.3%), hips (56.8%), and hands/wrists (46.9%), with characteristic involvement of the 2nd and 3rd metacarpophalangeal (MCP) joints being pathognomonic for hemochromatosis arthropathy. 1

Joint Distribution Pattern

The joint involvement in severe iron overload follows a distinctive pattern that differs from typical osteoarthritis:

Most Frequently Affected Joints (in order of prevalence):

• Ankles - 69.3% of patients with musculoskeletal symptoms 1
• Hips - 56.8% of patients 1
• Hands/Wrists - 46.9% of patients, particularly the 2nd and 3rd MCP joints which are pathognomonic 1
• Knees - commonly affected, with increased risk of knee replacement (HR 2.14) 1

Characteristic Features

The 2nd and 3rd metacarpophalangeal joints are the hallmark of hemochromatosis arthropathy - this pattern is highly specific and should immediately raise suspicion for iron overload when seen in younger patients with osteoarthritis-like symptoms 1. This is distinctly different from typical osteoarthritis, which preferentially affects the distal interphalangeal joints.

Clinical Presentation

The arthropathy associated with ferritin >1000 µg/L presents with:

• Earlier age of onset compared to typical osteoarthritis 1
• Bony enlargement in 65.8% of patients 2
• Synovitis in 13.6% (less common than bony changes) 2
• Chondrocalcinosis in approximately 50% of cases, particularly in wrists and knees 1, 3
• Exuberant osteophytes with rapid progression to cartilage loss 1

Radiographic Findings

When evaluating joints in patients with ferritin >1000 µg/L, look for:

• Joint space narrowing
• Osteophytes
• Subchondral cysts
• Chondrocalcinosis (present in 50% of cases) 1, 3

Critical Clinical Pitfalls

Important Caveat About Treatment Response

Hemochromatosis arthropathy does NOT respond to phlebotomy and can actually develop or worsen during maintenance therapy 1. This is crucial because while other organ manifestations (liver, heart, endocrine) may improve with iron depletion, joint disease is irreversible and progressive. This significantly impacts quality of life and represents a major source of morbidity even with appropriate iron management.

Risk of Joint Replacement

Patients with severe iron overload face substantially increased risks of requiring joint replacement surgery:

• Hip replacement: HR 2.77 (95% CI 2.27-3.38) 1
• Knee replacement: HR 2.14 (95% CI 1.58-2.88) 1
• Bilateral hip replacement: OR 5.86 (95% CI 2.36-14.57) 1

The mean age at joint replacement is 58.3 years 2, considerably younger than typical osteoarthritis patients.

Timing of Symptoms

Joint pain often precedes the diagnosis of hemochromatosis by an average of 9 years 2, meaning arthropathy may be the presenting feature. In the survey data, 86.5% of hemochromatosis patients described arthritis or joint pain 1, making it the most common extrahepatic manifestation.

Differential Diagnosis Considerations

The arthropathy can mimic:

• Calcium pyrophosphate deposition disease (pseudogout)
• Rheumatoid arthritis (when synovitis is present)
• Primary osteoarthritis

However, the combination of 2nd/3rd MCP involvement, younger age, and chondrocalcinosis should prompt immediate evaluation for iron overload 3, 4.

Management Implications

Since joint disease doesn't respond to phlebotomy 1:

• Treatment is limited to analgesics, NSAIDs, physiotherapy, and ultimately joint replacement 1
• Early identification is critical to prevent progression in other organs, even though joint damage may be irreversible
• Patients require specific rheumatologic management alongside iron depletion therapy

The arthropathy represents a major quality-of-life burden that persists despite successful treatment of iron overload, emphasizing the importance of early diagnosis before irreversible joint damage occurs.